About FSHD Canada Foundation
Funded Research

Pre-clinical testing for FSHD CRISPR-inhibition therapy

Principle Investigator: Associate Professor Peter Jones Research Institution: University of Nevada CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or…

Read More

Facio Therapies

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…

Read More

Development of next-generation AAV vectors for effective CRISPR inhibition of FSHD

Investigator: Charis L. Himeda, PhD, Research Assistant Professor, University of Nevada, Reno School of Medicine, Reno NV USA CRISPR technology provides an avenue for specifically targeting and manipulating virtually any…

Read More

Identify Biomarkers for FSHD Using Omics Approaches

Investigator: Yi-Wen Chen, Ph.D. (Children’s Research Institute in Silver Spring, Maryland) Biomarkers are biological changes that can be used as indicators of physiological and disease states. Biomarkers can be valuable…

Read More

Stryka-001 treatment in the FSHD-like mouse model

Investigator: Dean Burkin, PhD, and Peter Jones, PhD (University of Nevada, Reno School of Medicine) This is a project to validate the efficacy of a potential drug therapy for FSHD…

Read More

A Xenograft Model of FSHD for Testing Therapeutics

Investigator: Robert J Bloch PhD, Professor of Physiology
 at the University of Maryland Facioscapulohumeral muscular dystrophy (FSHD) affects 1 in approximately 15,000 individuals worldwide. One of the obstacles in developing treatments…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca